Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Lung cancer patients can expect improved long term survival under a new treatment combination, according to new Irish research published today. The patients with lung cancer who received an ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

In tests with mice, a protein derived from the virus boosted the immune system's ability to kill cancer cells.

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Combination treatment could also benefit patients with lung, bowel, pancreatic and other solid cancers who don’t respond to ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients ...